BioMed Research Updates: ARRY, ACCP.OB, MCLN.OB |
 |
 |
| Wednesday, 16 December 2009 19:31 |
|
1.) Array BioPharma (NASDAQ: ARRY) Rodman & Renshaw 12/14/09 Rated Market Outperform / Speculative Risk 12-Month Price Target of $10, Last Price $2.66 2.) Access Pharma (OTC: ACCP.OB) NextWave Research 12/16/09 Rated Spec Buy, $7 Price Target, Last Price $3.20 3.) MedClean Technologies (OTC: MCLN.OB) Goldman Small Cap Research 12/9/09 Rated Spec Buy with Near-Term Price Target $0.14, 2010 Price Target $0.40, Last Price $0.03 Disclosure: Long ACCP.OB BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read in the About Us Section Add this page to your favorite Social Bookmarking websites            |
Below are four stock research reports published within the past week and available to view or download at the 
about 1 hour ago
NHS education reforms 'lack detail' http://t.co/YiUKVEsS
about 1 hour ago
Molecular 'on-off' switch for Parkinson's disease discovered http://t.co/wZ1N0xhq
about 1 hour ago
Alnylam and PBL Sign License Agreement for Baulcombe & Hamilton RNAi Patent http://t.co/CnJ8fKok
about 1 hour ago
Roche's dalcetrapib failure fuels HDL debate, but CETP not done yet http://t.co/8H9JRnp9
about 1 hour ago
Modest Gains Vanish As Stocks Reverse Lower http://t.co/AXlpfiAP
about 1 hour ago
Reading: One More Reason the Market's Pullback is Not Over http://t.co/iSZ0oYUq
about 8 hours ago
Novo’s Insulin Pill Quest is Holy Grail for Novo: Health http://t.co/1NixK9Mx
about 8 hours ago
Bayer's Nexavar fails in lung cancer but FDA staff keen on Xarelto for ACS http://t.co/9VZRVqqD
Free Phone Trade Alerts
